ReviewMolecular biomedicine2025
Emerging role of N-acetyltransferase 10 in diseases: RNA ac4C modification and beyond.
Review in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- RNA N4-acetylcytidine modification in health and cancer: molecular mechanisms, cellular plasticity, and therapeutic opportunities.Biomarker research · 2026Review
- Structure-guided identification and experimental validation of NAT10-targeting small molecules in colorectal cancer cells.Journal of computer-aided molecular design · 2026Article
- Propofol regulates SLC6A2 expression via NAT10-mediated ac4C modification to modulate excessive mitophagy and hippocampal neuron dysfunction in aged postoperative cognitive dysfunction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.Cardiovascular diabetology · 2026Article
- The functions, mechanisms and clinical relevance of RNA and protein acetyltransferase NAT10: a comprehensive review.Cell biology and toxicology · 2026Review
- NAT10 drives ovarian cancer progression via NLRP3 mRNA ac4C modification.Discover oncology · 2026Article
- ac4C modification sites prediction in human mRNA: a complete review.Briefings in bioinformatics · 2026Review
- Integrative single-cell and machine-learning analysis identifies acBMC cancer · 2026Article
- NAT10-mediated ac4C modifications regulate glioblastoma progression.Cell death & disease · 2026Article
- Identification of N4-Acetylcytidine-Related Biomarkers in Adult Asthma: An Integrative Multi-Omics Study.Journal of inflammation research · 2026Article
- N4-acetylcytidine modification bridges metabolic reprogramming and immune evasion in cancer: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Article
- Metabolic control of RNA methylation in rheumatoid arthritis: from synovial stress to pathogenic cellular adaptation.Frontiers in immunology · 2026Review
- A neuron-distributed DEK integrates ac4C modification and neuroinflammation in pathogenesis of Parkinson disease: evidence from Mendelian randomization, multi-omics andFrontiers in neuroscience · 2026Article
- Identification of the Role ofVeterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.